Group One Trading, L.P. Ocugen, Inc. Transaction History

Group One Trading, L.P.

$2.4 Billion
Q3 2024

A detailed history of Group One Trading, L.P. transactions in Ocugen, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 424,926 shares of OCGN stock, worth $327,193. This represents 0.02% of its overall portfolio holdings.

Number of Shares

424,926

Previous 651,381 34.77%

Holding current value

$327,193

Previous $1.01 Million 58.37%

% of portfolio

0.02%

Previous 0.03%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.98 - $1.95 $221,925 - $441,587	-226,455 Reduced 34.77%	424,926 $420,000
Q2 2024 Aug 14, 2024	BUY	$1.18 - $1.98 $31,370 - $52,638	26,585 Added 4.25%	651,381 $1.01 Million
Q1 2024 May 10, 2024	BUY	$0.5 - $1.83 $61,372 - $224,623	122,745 Added 24.45%	624,796 $1.02 Million
Q4 2023 Feb 14, 2024	BUY	$0.36 - $0.57 $121,290 - $192,043	336,918 Added 204.03%	502,051 $286,000
Q3 2023 Nov 09, 2023	BUY	$0.4 - $0.62 $17,537 - $27,183	43,844 Added 36.15%	165,133 $66,000
Q2 2023 Aug 09, 2023	SELL	$0.45 - $0.88 $5,768 - $11,279	-12,818 Reduced 9.56%	121,289 $65,000
Q1 2023 May 12, 2023	BUY	$0.82 - $1.33 $3,371 - $5,467	4,111 Added 3.16%	134,107 $113,000
Q4 2022 Feb 09, 2023	BUY	$1.11 - $1.87 $92,319 - $155,529	83,171 Added 177.62%	129,996 $168,000
Q3 2022 Nov 09, 2022	SELL	$1.75 - $3.1 $268,450 - $475,540	-153,400 Reduced 76.61%	46,825 $83,000
Q2 2022 Aug 11, 2022	BUY	$1.83 - $3.45 $256,018 - $482,658	139,901 Added 231.92%	200,225 $455,000
Q1 2022 May 12, 2022	SELL	$2.34 - $4.72 $77,699 - $156,727	-33,205 Reduced 35.5%	60,324 $199,000
Q4 2021 Feb 11, 2022	BUY	$4.38 - $15.67 $409,657 - $1.47 Million	93,529 New	93,529 $426,000

Others Institutions Holding OCGN

# of Institutions

124

Shares Held

78.3M

Call Options Held

535K

Put Options Held

523K

View Full List

About Ocugen, Inc.

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $167M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

More about OCGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.

Account

Group One Trading, L.P. Ocugen, Inc. Transaction History